SaTX-1

SaTX-1 is a preclinical-stage monoclonal antibody being developed by StarkAge Therapeutics, a biotechnology company focused on targeting cellular senescence. The drug is designed to target Dipeptidyl peptidase 4 (DPP4), also known as CD26, a transmembrane protein that is highly overexpressed on the surface of senescent cells and various cancer cells. By binding to DPP4-expressing cells, SaTX-1 is intended to mediate their elimination or inhibition, potentially serving as a senolytic therapy or a targeted immunotherapy for the treatment of cancer. It is part of a broader pipeline at StarkAge Therapeutics that includes antibody-drug conjugates (ADCs) like STX-1, which also target the DPP4 marker.